NCT03667170 2026-03-25
KN035 for dMMR/MSI-H Advanced Solid Tumors
3D Medicines
Phase 2 Recruiting
Clinical Trials
9 trialsNCT04891198 2026-03-25
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
3D Medicines
Phase 2 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT05112991 2026-03-25
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
3D Medicines
Phase 2 Recruiting
NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT06643208 2025-06-26
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Fujian Provincial Hospital
Recruiting
NCT05941325 2025-05-18
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Recruiting